Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc

Bullboard Posts

Post by pro_traderon Oct 13, 2008 9:03pm

554 Views

Post# 15523440

Important update concerning Company Connect forum

Just wanted to apologize to all readers who hoped to have an opportunity to talk with the CEO of XSNX on the Beacon website last Friday. Apparently there was a scheduling problem and Beacon had to cancel the Company Connnect. Tom and XSNX had nothing to do with the miscommunication and I apologize for forgetting to inform you of the scheduling conflict.

Bullboard Posts

The Market Online’s Weekly Gold Report – Nov. 27, 2024